{"preliminary_commentary":{"by_channel":{"x_thread":78,"bluesky_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00098475\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"E4A03","nct_id":"NCT00098475","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=e4a03-nct00098475. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive lenalidomide PO QD on days 1-21 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20.","label":"Arm I (lenalidomide, dexamethasone)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive lenalidomide and acetylsalicylic acid as in Arm I and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.","label":"Arm II (lenalidomide, low-dose dexamethasone)","type":"EXPERIMENTAL"},{"description":"Patients with no response after treatment on Arm I: Patients receive thalidomide PO QD on days 1-28 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20","label":"Arm III (thalidomide, dexamethasone)","type":"ACTIVE_COMPARATOR"},{"description":"Patients with no response after treatment on Arm II: Patients receive thalidomide as in arm III and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.","label":"Arm IV (thalidomide, low-dose dexamethasone)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-10-23","type":"ESTIMATED"},"conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":{"count":452,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hemady","Hexadecadrol","Hexadrol","LenaDex","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Lenalidomide","otherNames":["CC 5013","CC-5013","CC5013","CDC 501","Revlimid"],"type":"DRUG"},{"name":"Thalidomide","otherNames":["(+)-Thalidomide","(-)-Thalidomide",".alpha.-Phthalimidoglutarimide","2, 6-Dioxo-3-phthalimidopiperidine","Alpha-Phthalimidoglutarimide","Contergan","Distaval","Kevadon","N-(2,6-Dioxo-3-piperidyl)phthalimide","N-Phthaloylglutamimide","N-Phthalylglutamic Acid Imide","Neurosedyn","Pantosediv","Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-","Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-","Sedalis","Sedoval K-17","Sedoval K17","Softenon","Synovir","Talimol","Thalomid"],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2008-11-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Proportion of Patients With Objective Response (First Phase, Step 1)","timeFrame":"Assessed every 4 weeks for 16 weeks during Step 1"}],"references":[{"citation":"Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013 Apr 18;121(16):3147-52. doi: 10.1182/blood-2012-07-443606. Epub 2013 Feb 19.","pmid":"23422747","type":"DERIVED"},{"citation":"Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20;118(16):4359-62. doi: 10.1182/blood-2011-03-342089. Epub 2011 Aug 22.","pmid":"21860025","type":"DERIVED"},{"citation":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21.","pmid":"19853510","type":"DERIVED"}],"start_date":{"date":"2004-11-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT00098475"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/e4a03-nct00098475"}